恒瑞医药自主研发的创新型抗肿瘤药物HRS-2329 片获批开展临床试验

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of HRS-2329 tablets, an innovative anti-tumor drug developed by the company, which shows promising anti-tumor activity in preclinical animal models and is intended for the treatment of advanced solid tumors with RAS mutations or amplifications [1] Group 1 - HRS-2329 tablets are a self-developed innovative anti-tumor drug by the company [1] - The drug has demonstrated good anti-tumor activity in preclinical animal models [1] - There are currently no similar drugs approved for marketing domestically or internationally [1] Group 2 - The company has invested approximately 60.15 million yuan in the research and development of the HRS-2329 project to date [1]